for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Starpharma Holdings Limited

SPL.AX

Latest Trade

1.10AUD

Change

-0.02(-1.79%)

Volume

306,324

Today's Range

1.09

 - 

1.12

52 Week Range

1.09

 - 

2.52

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Pricing

Previous Close
1.12
Open
1.12
Volume
306,324
3M AVG Volume
13.04
Today's High
1.12
Today's Low
1.09
52 Week High
2.52
52 Week Low
1.09
Shares Out (MIL)
406.08
Market Cap (MIL)
461.08
Forward P/E
-113.50
Dividend (Yield %)
--

Next Event

Starpharma Holdings Ltd Annual Shareholders Meeting

Latest Developments

更多

Starpharma Holdings Says Viraleze To Launch In Admenta Italia Group Pharmacies In Italy

Starpharma Says Viraleze Spl7013 Virucidal Against Sars-Cov-2 Delta Variant

Starpharma Says Uk Retail Partner Received Correspondence From UK MHRA

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Starpharma Holdings Limited

Starpharma Holdings Limited is an Australia-based biopharmaceutical company. The Company is engaged in development of dendrimer products for pharmaceutical, life science and other applications. The Company has two core development programs: VivaGel portfolio and Dendrimer Enhanced Product (DEP) drug delivery. VivaGel BV for bacterial vaginosis (BV) is a women’s health product. It is available for sale under the brand names, Betafem BV Gel (UK), Betadine BV (Europe), Betadine BV Gel (Asia) and Fleurstat BVgel (Australia and New Zealand). DEP is a drug delivery platform, which provides demonstrated reproducible preclinical benefits across various internal and partnered DEP programs, including improved efficacy, safety, and survival. The Company has three internal DEP products includes DEP docetaxel, DEP cabazitaxel and DEP irinotecan. These internal DEP Products are in clinical development. The Company develops several products internally and others via commercial partnerships.

Industry

Biotechnology & Drugs

Contact Info

4-6 Southampton Crescent, Abbotsford

MELBOURNE, VIC

3067

Australia

+61.3.85322700

http://www.starpharma.com

Executive Leadership

Robert Bain Thomas

Independent Non-Executive Chairman of the Board

Jacinth K. Fairley

Chief Executive Officer, Managing Director, Executive Director

Nigel J. Baade

Chief Financial Officer, Company Secretary

David J. Owen

Vice President - Research

Jeremy R. Paull

Vice President - Development and Regulatory Affairs

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, AUD)

2019

0.0K

2020

0.0K

2021

0.0K

2022(E)

0.0K
EPS (AUD)

2019

-0.040

2020

-0.040

2021

-0.050

2022(E)

-0.010
Price To Earnings (TTM)
--
Price To Sales (TTM)
132.23
Price To Book (MRQ)
7.40
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.87
LT Debt To Equity (MRQ)
0.76
Return on Investment (TTM)
-41.46
Return on Equity (TTM)
-35.14

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up